, Tracking Stock Market Picks
Enter Symbol:
Rating: ENDP

Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) upgraded to Buy by Standpoint Research

Friday,  Nov 13, 2015  10:25 AM ET by Lynn Gilbert

Standpoint Research upgraded Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) to Buy.
Previously, Standpoint Research rated Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) to Hold on 04/10/2013, when the stock price was valued at $34.60.

Endo Pharmaceuticals Holdings Inc., through its wholly owned subsidiaries, Endo Pharmaceuticals Inc. and Endo Inc., is engaged in the research, development, sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy